| 1 |
NCT03487471 |
Recruiting |
Comparison of Real-time and Shear Wave Elastography |
|
- Diagnostic Test: Real-time elastography
- Diagnostic Test: Shear wave elastography
|
Interventional
|
Not Applicable |
- University Hospital, Basel, Switzerland
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- assessment of dignity of breast lesion by use of real-time elastography
- assessment of dignity of breast lesion by use of shear wave elastography
- Examinators learning curve
|
98 |
Female |
18 Years and older (Adult, Older Adult) |
NCT03487471 |
Elasto Trial |
Elasto |
March 1, 2018 |
October 1, 2020 |
October 1, 2020 |
April 4, 2018 |
April 4, 2018 |
|
- St Claraspital
Basel, Switzerland
|
|
| 2 |
NCT02997540 |
Recruiting |
Effect of Body Position and Probe Position on the Localization of Breast Mass |
|
|
Observational
|
|
|
Industry |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- movement of a given ultrasound breast lesion
|
35 |
Female |
21 Years to 70 Years (Adult, Older Adult) |
NCT02997540 |
BVN G-1000 |
|
November 2016 |
October 2017 |
October 2017 |
December 20, 2016 |
April 27, 2017 |
|
- Evanston Hospital
Evanston, Illinois, United States
|
|
| 3 |
NCT02566499 |
Not yet recruiting |
Performance Assessment of a First Generation Breast Microwave Imaging System: Study of Breast Abnormalities Detection |
|
- Device: Breast Microwave Imaging
|
Interventional
|
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Diagnostic Accuracy (NO units)
- Sensitivity (NO units)
- Specificity (NO units)
|
14 |
Female |
40 Years to 85 Years (Adult, Older Adult) |
NCT02566499 |
B2015:73 |
|
April 1, 2019 |
December 2019 |
June 2020 |
October 2, 2015 |
May 1, 2018 |
|
|
|
| 4 |
NCT02522468 |
Recruiting |
A Trial of RSL Versus WL for Malignant Breast Disease |
|
- Procedure: Radioactive Seed Localization
- Procedure: Wire Localization
|
Interventional
|
Not Applicable |
- Lejla Hadzikadic-Gusic
- Carolinas Healthcare System
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Surgical Resection Margins
|
400 |
Female |
20 Years to 99 Years (Adult, Older Adult) |
NCT02522468 |
LCI-BRE-BCS-RSL-001 |
BCS-RSL-001 |
July 2015 |
July 2020 |
July 2020 |
August 13, 2015 |
May 3, 2018 |
|
- Carolinas Healthcare System
Charlotte, North Carolina, United States
|
|
| 5 |
NCT03304080 |
Recruiting |
Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in Her-positive, Her2-positive Metastatic Breast |
- Breast Neoplasms
- Breast Diseases
|
- Drug: Anastrozole
- Drug: Palbociclib
- Drug: Trastuzumab
- Drug: Pertuzumab
|
Interventional
|
Phase 1
Phase 2 |
- Icahn School of Medicine at Mount Sinai
- Herbert Irving Comprehensive Cancer Center
- Weill Medical College of Cornell University
- New York University School of Medicine
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Dose-Limiting Toxicity (DLT)
- Maximum Tolerated Dose (MTD)
- Clinical Benefit Rate (CBR)
- (and 2 more...)
|
36 |
Female |
18 Years and older (Adult, Older Adult) |
NCT03304080 |
GCO 17-0919 |
|
December 20, 2017 |
November 1, 2019 |
November 1, 2019 |
October 6, 2017 |
June 14, 2018 |
|
- Mount Sinai Beth Israel Comprehensive Cancer Center West
New York, New York, United States - Perlmutter Cancer Center NYU Langone
New York, New York, United States - Mount Sinai West
New York, New York, United States - (and 2 more...)
|
|
| 6 |
NCT02964234 |
Recruiting |
Empowering Latinas to Obtain Breast Cancer Screenings |
- Breastcancer
- Breast Diseases
|
- Behavioral: Empowerment
- Behavioral: Education
|
Interventional
|
Not Applicable |
- University of Illinois at Chicago
- The Resurrection Project
- Juan Diego Centro Comunitario
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Screening
|
- Number of participants who have obtained breast cancer screening
|
150 |
Female |
52 Years to 75 Years (Adult, Older Adult) |
NCT02964234 |
K01CA193918 |
|
March 1, 2017 |
August 2021 |
August 2021 |
November 16, 2016 |
May 3, 2018 |
|
- The Resurrection Project
Chicago, Illinois, United States - University of Illinois at Chicago
Chicago, Illinois, United States - Juan Diego Centro Comunitario
Chicago, Illinois, United States
|
|
| 7 |
NCT01937039 |
Recruiting |
Johns Hopkins Breast Cancer Program Longitudinal Repository |
- Breast Cancer
- Benign Breast Disease
|
- Procedure: Sample collection
|
Observational
|
|
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
|
Other |
- Observational Model: Other
- Time Perspective: Prospective
|
|
1000 |
All |
18 Years and older (Adult, Older Adult) |
NCT01937039 |
J0888
SKCCC J0888 |
|
April 2009 |
January 2030 |
January 2030 |
September 9, 2013 |
April 24, 2018 |
|
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, United States
|
|
| 8 |
NCT03020888 |
Recruiting |
Magseed Magnetic Marker Localization |
- Disorders of Breast
- Breast Lesions
|
- Device: Magseed and Sentimag
|
Interventional
|
Not Applicable |
- Endomagnetics Inc
- M.D. Anderson Cancer Center
|
Industry / Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percent retrieval rate of the index lesion and Magseed
- Rates of device-related adverse events
- Radiological Ease of Placement
- (and 5 more...)
|
120 |
Female |
18 Years and older (Adult, Older Adult) |
NCT03020888 |
US-002 |
|
January 2017 |
February 2018 |
May 2018 |
January 13, 2017 |
February 5, 2018 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
|
| 9 |
NCT02929420 |
Recruiting |
A Clinical Study on the Efficacy and Safety of the Treatment of Hyperplasia of Mammary Glands With Xiaoru Sanjie Capsule |
- Fibrocystic Disease of Breast
|
- Drug: Xiaoru Sanjie capsules
- Drug: Xiao Yao pills
|
Interventional
|
Phase 4 |
- First Affiliated Hospital Xi'an Jiaotong University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- the size of breast lumps
- the scope of breast lumps
- the hardness of breast lumps
- (and 5 more...)
|
600 |
Female |
18 Years to 65 Years (Adult, Older Adult) |
NCT02929420 |
ry-2016-08 |
|
October 2016 |
December 2017 |
December 2017 |
October 11, 2016 |
October 11, 2016 |
|
- Yu Ren
Xi'an, Shaanxi, China
|
|
| 10 |
NCT03038152 |
Recruiting |
Study the Use of Magseed and Sentimag to Localize Axillary Lymph Nodes |
- Disorder of Breast
- Breast Cancer
|
- Device: Magseed Marker
- Procedure: Lymph Node Removal Procedure
- Procedure: Ultrasound/Mammogram
- (and 2 more...)
|
Interventional
|
Phase 4 |
- M.D. Anderson Cancer Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Retrieval Rate of the Clipped Node and Magseed® in Excised Specimen
|
50 |
Female |
18 Years and older (Adult, Older Adult) |
NCT03038152 |
2016-0806
NCI-2017-00649 |
|
April 11, 2017 |
April 2020 |
April 2021 |
January 31, 2017 |
March 23, 2018 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
|
| 11 |
NCT02810236 |
Recruiting |
Focal Breast Pain: Does a Normal Ultrasound Provide Reassurance? |
- Breast Diseases
- Mastodynia
- Anxiety
|
- Procedure: Ultrasound
- Behavioral: Discussion
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Diagnostic
|
- Change in anxiety using modified STAI questionnaire
|
160 |
Female |
30 Years and older (Adult, Older Adult) |
NCT02810236 |
Pro00070445 |
|
February 13, 2018 |
June 2018 |
June 2018 |
June 22, 2016 |
February 15, 2018 |
|
- Duke University Medical Center
Durham, North Carolina, United States
|
|
| 12 |
NCT03374826 |
Recruiting |
PET-MRI for Axillary Staging in Node Negative Breast Cancer Patients |
- Breast Cancer
- Breast Neoplasms
- Breast Diseases
|
- Diagnostic Test: Dedicated axillary hybrid PET-MRI
|
Interventional
|
Not Applicable |
- Maastricht University Medical Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Accuracy of dedicated hybrid PET/MRI
- Accuracy of T2w MRI, DWI and Hybrid PET/MRI
|
125 |
Female |
18 Years and older (Adult, Older Adult) |
NCT03374826 |
NL62441.068.17 |
|
February 22, 2018 |
February 2020 |
February 2020 |
December 15, 2017 |
February 28, 2018 |
|
- Maastricht University Medical Center
Maastricht, Netherlands
|
|
| 13 |
NCT03373708 |
Not yet recruiting |
Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer |
- Breast Cancer
- Chemotherapy
- Endocrine Breast Diseases
|
- Drug: Epirubicin
- Drug: Cyclophosphamide
- Drug: Docetaxel
- (and 3 more...)
|
Interventional
|
Phase 2
Phase 3 |
- Zhiyong Yu
- Shandong Cancer Hospital and Institute
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Disease-free survival (DFS)
- Expression of female hormone levels
- Overall survival (OS)
|
200 |
Female |
18 Years to 70 Years (Adult, Older Adult) |
NCT03373708 |
ShandongCHI-03 |
|
December 20, 2017 |
December 20, 2019 |
December 20, 2019 |
December 14, 2017 |
December 18, 2017 |
|
|
|
| 14 |
NCT02928978 |
Not yet recruiting |
Ruxolitinib for Premalignant Breast Disease |
- Ductal Carcinoma In Situ
- Atypical Lobular Hyperplasia
- Atypical Ductal Hyperplasia
- Lobular Carcinoma In Situ
|
- Drug: Ruxolitinib
- Drug: Placebo (for Ruxolitinib)
|
Interventional
|
Phase 2 |
- Julie Nangia
- Incyte Corporation
- Translational Breast Cancer Research Consortium
- Baylor Breast Care Center
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Prevention
|
- Change in Apoptosis
- pSTAT5
|
100 |
All |
18 Years and older (Adult, Older Adult) |
NCT02928978 |
BaylorBCC |
TBCRC 042 |
January 2017 |
January 2019 |
January 2020 |
October 10, 2016 |
February 9, 2017 |
|
- Baylor College of Medicine
Houston, Texas, United States
|
|
| 15 |
NCT03500380 |
Recruiting |
A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer |
- Breast Neoplasms
- Breast Diseases
- Capecitabine
- (and 2 more...)
|
- Drug: RC48-ADC
- Drug: Lapatinib
- Drug: Capecitabine
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-free Survival (PFS) as Assessed by an IRC
- Progression-free Survival (PFS) as Assessed by Investigator
- Objective Response Rate （ORR）
- (and 4 more...)
|
228 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT03500380 |
RC48-C006 |
|
April 2018 |
December 2019 |
December 2020 |
April 17, 2018 |
April 17, 2018 |
|
- Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing, China - The First Hospital of China Medical University
Shengyang, Liaoning, China - Liaoning Cancer Hospital & Institute
Shenyang, Liaoning, China - (and 40 more...)
|
|
| 16 |
NCT01427400 |
Recruiting |
The Use of Botulinum Toxin A in Two-Stage Tissue Expander/ Implant Breast Reconstruction |
- Breast Neoplasms
- Neoplasms by Site
- Neoplasms
- (and 2 more...)
|
- Drug: Botulinum Toxin-A
- Drug: Saline
|
Interventional
|
Phase 4 |
- University of British Columbia
- Vancouver Coastal Health
- Providence Health & Services
- Fraser Health
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change from Baseline in Quality of life and patient satisfaction using the Breast-Q
- Patient-reported pain,using the BPI (Brief Pain Inventory) and Pain Diary during the expansion phase (initial to final expansion) and in the long-term period (6 and 12 months).
- Aesthetic outcome
|
128 |
Female |
21 Years and older (Adult, Older Adult) |
NCT01427400 |
H10-03166 |
Botox |
October 2011 |
December 2016 |
December 2017 |
September 1, 2011 |
July 29, 2016 |
|
- Plastic, Reconstructive and Cosmetic Surgery
Surrey, British Columbia, Canada - Canada, British Columbia
Vancouver, British Columbia, Canada
|
|
| 17 |
NCT01917279 |
Recruiting |
Capecitabine Maintenance Therapy Following Capecitabine Combined With Docetaxel in Treatment of mBC |
- Breast Neoplasms
- Neoplasms by Site
- Neoplasm Metastasis
- (and 2 more...)
|
- Drug: Docetaxel plus Capecitabine
- Drug: Capecitabine
|
Interventional
|
Phase 3 |
- Binghe Xu
- Hoffmann-La Roche
- Chinese Academy of Medical Sciences
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression Free Survival (PFS)
- Adverse events (AEs)
- Overall survival (OS):
- (and 4 more...)
|
928 |
All |
18 Years and older (Adult, Older Adult) |
NCT01917279 |
ML28898 |
CAMELLIA |
October 2013 |
July 2016 |
September 2018 |
August 6, 2013 |
November 25, 2013 |
|
- Cancer Institute and Hospital, Chinese Academy Of Medical Sciences
Beijing, China
|
|
| 18 |
NCT02909452 |
Recruiting |
Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors |
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Neoplasms by Histologic Type
- (and 11 more...)
|
- Drug: Entinostat
- Drug: Pembrolizumab
|
Interventional
|
Phase 1 |
- Syndax Pharmaceuticals
- Merck Sharp & Dohme Corp.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and adverse events (AEs) resulting in the permanent discontinuation of study drug, and deaths occurring within the reporting period required for the study
- Changes from baseline in laboratory results
- Changes from baseline in vital signs
- (and 7 more...)
|
30 |
All |
18 Years and older (Adult, Older Adult) |
NCT02909452 |
SNDX-275-0141 |
|
September 2016 |
December 2017 |
February 2018 |
September 21, 2016 |
February 27, 2017 |
|
- The START Center for Cancer Care
San Antonio, Texas, United States
|
|
| 19 |
NCT02701244 |
Recruiting |
A Registry Study of Breast Microseed Treatment |
|
- Radiation: Permanent Breast Seed Implant (PBSI)
|
Observational
|
|
- Concure Oncology-Breast Microseed Inc.
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Serious Adverse Events (SAE)
- Breast Cancer Recurrence
- Permanent Breast Seed Implant (PBSI) Side Effects
- (and 2 more...)
|
420 |
Female |
50 Years and older (Adult, Older Adult) |
NCT02701244 |
BMS-001 |
|
July 2016 |
July 2021 |
July 2026 |
March 8, 2016 |
March 19, 2018 |
|
- Allegheny General Hospital
Pittsburgh, Pennsylvania, United States - Mary Washington Hospital
Fredericksburg, Virginia, United States - Swedish Cancer Institute
Seattle, Washington, United States
|
|
| 20 |
NCT02820961 |
Recruiting |
Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer |
- Breast Cancer
- Estrogen Receptor Positive Breast Cancer
|
- Drug: entinostat
- Drug: exemestane
|
Interventional
|
Phase 1 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Cmax, maximum plasma concentration
- Tmax, time at which maximum plasma concentration was observed
- AUC0-t, area under the plasma concentration-time curve from time zero to the last measurable concentration
- (and 8 more...)
|
40 |
Female |
18 Years to 85 Years (Adult, Older Adult) |
NCT02820961 |
SNDX-275-0130 |
|
June 2016 |
June 2017 |
June 2018 |
July 1, 2016 |
February 23, 2017 |
|
- Sarah Cannon Research Institute HealthONE
Denver, Colorado, United States - Florida Cancer Specialists
Sarasota, Florida, United States - Sarah Cannon Research Institute
Nashville, Tennessee, United States
|
|
| 21 |
NCT03525990 |
Recruiting |
Study Evaluating the Impact of Electronic Surveys on Patient-physician Communication and Quality of Life in Breast Cancer Patients |
- Breast Neoplasm Malignant Female
|
|
Interventional
|
Phase 3 |
- Dr. Vera Trommet
- Klinikum Wels-Grieskirchen
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Patient-physician communication
- Quality of life
- Frequency of discontinuations of therapy
- Duration of communication between physician and patient
|
150 |
Female |
Child, Adult, Older Adult |
NCT03525990 |
2017/01 |
|
January 10, 2018 |
January 2021 |
January 2021 |
May 16, 2018 |
May 16, 2018 |
|
- A.ö. Krankenhaus St. Josef Braunau GmbH
Braunau Am Inn, Upper Austria, Austria - Klinikum Wels-Grieskirchen GmbH
Wels, Upper Austria, Austria
|
|
| 22 |
NCT03524170 |
Recruiting |
RACHEL1: Radiation and CHEckpoint bLockade Trial in Patients With Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer |
- Malignant Neoplasm of Breast
|
- Drug: M7824
- Radiation: Radiation Therapy
|
Interventional
|
Phase 1 |
- M.D. Anderson Cancer Center
- EMD Serono
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Recommended phase II dose (RP2D) of M7824 and radiation therapy in patients with metastatic HR+/HER2- breast cancer determined by dose limiting toxicity (DLT)
- Safety and tolerability of M7824 and radiation therapy in patients with metastatic HR+/HER2- breast cancer.
- Progression-free survival (PFS)
- (and 3 more...)
|
20 |
All |
18 Years and older (Adult, Older Adult) |
NCT03524170 |
2017-0499
NCI-2018-00961 |
|
April 30, 2018 |
September 2019 |
September 2020 |
May 14, 2018 |
May 24, 2018 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
|
| 23 |
NCT03501394 |
Recruiting |
What Factors Affect Breast Cancer Neoadjuvant Chemotherapy Efficacy? |
- Breast Neoplasm Malignant Breast Tissue
|
- Other: Magnetic Resonance Imaging
- Other: Histopathological Analysis
- Other: Health Questionnaire
|
Interventional
|
Not Applicable |
- University of Aberdeen
- NHS Grampian
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Baseline: Water diffusion probability density function (Full-Width-At-Half-Maximum, FWHM, units of micrometre)
- Post Cycle 1: Water diffusion probability density function (Full-Width-At-Half-Maximum, FWHM, units of micrometre)
- Post Cycle 3: Water diffusion probability density function (Full-Width-At-Half-Maximum, FWHM, units of micrometre)
- (and 23 more...)
|
25 |
Female |
18 Years and older (Adult, Older Adult) |
NCT03501394 |
2/108/7
234794
17/LO/1777 |
|
May 2, 2018 |
June 2019 |
June 2019 |
April 18, 2018 |
May 3, 2018 |
|
- NHS Grampian
Aberdeen, Aberdeenshire, United Kingdom
|
|
| 24 |
NCT03463954 |
Not yet recruiting |
Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors |
- Malignant Neoplasm of Breast
|
- Device: Novilase Laser ablation
|
Interventional
|
Not Applicable |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of target tumors completely ablated in one procedure
- Frequency of adverse events (categorized using the NCI Common Terminology for Adverse Events (CTCAE) v4.0 guidelines) post-laser ablation and post-surgery
- Patient reported rate of return to activities of daily living post-laser ablation and post-surgery
- (and 2 more...)
|
122 |
Female |
18 Years and older (Adult, Older Adult) |
NCT03463954 |
BR-003 |
|
June 2018 |
August 2019 |
December 2019 |
March 13, 2018 |
March 13, 2018 |
|
|
|
| 25 |
NCT03429907 |
Recruiting |
An Early Stress-Reduction Intervention in Patients With Newly Diagnosed Breast Cancer |
- Malignant Neoplasm of Breast
|
- Behavioral: Mind-Body Exercises
- Behavioral: Questionnaires
|
Interventional
|
Not Applicable |
- M.D. Anderson Cancer Center
- Hackett Foundation
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Effect of the Stress-Reduction Intervention on Changes in Patient-Reported Outcomes From T0 to T2 and T3
- Changes in Inflammatory Markers
- Associations of patient-reported stress and neuroendocrine biomarkers
- (and 4 more...)
|
140 |
Female |
18 Years and older (Adult, Older Adult) |
NCT03429907 |
2016-0600 |
|
December 5, 2017 |
December 2019 |
December 2020 |
February 12, 2018 |
May 11, 2018 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
|
| 26 |
NCT03425656 |
Recruiting |
Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Trastuzumab (AryoTrust®) Versus Herceptin® in Breast Cancer |
- Malignant Neoplasm of Breast
|
- Drug: Trastuzumab plus docetaxel (for 4 21-day cycles) after four 14-day cycles of Doxorubicin plus cyclophosphamide
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- pathologic Complete Response
- clinical Complete Response
- clinical Partial Response
- (and 5 more...)
|
108 |
Female |
18 Years to 65 Years (Adult, Older Adult) |
NCT03425656 |
TRA.ARY.RS.94 (III) |
|
July 9, 2016 |
October 30, 2018 |
October 30, 2018 |
February 7, 2018 |
February 7, 2018 |
|
- Imam Khomeini hospital
Tehran, Iran, Islamic Republic of
|
|
| 27 |
NCT03379428 |
Recruiting |
Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer |
- Breast Neoplasms
- Malignant Neoplasm of Breast
|
- Drug: Trastuzumab
- Drug: Ibrutinib 560 mg
- Drug: Ibrutinib 840 mg
- Drug: Ibrutinib 420 mg
|
Interventional
|
Phase 1
Phase 2 |
- US Oncology Research
- AbbVie
- Pharmacyclics LLC.
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Phase I: Maximum Tolerated Dose
- Phase II: Clinical Benefit Rate
- Objective Response Rate
- (and 5 more...)
|
51 |
Female |
18 Years and older (Adult, Older Adult) |
NCT03379428 |
14059
14-05914-059 |
|
November 29, 2017 |
December 2019 |
December 2021 |
December 20, 2017 |
December 21, 2017 |
|
- 10 sites incl TX, WA, VA, and NV
Dallas, Texas, United States
|
|
| 28 |
NCT03366428 |
Recruiting |
Phase 1 Study to Evaluate the Effect of DS-8201a on the QT/QTc Interval in HER2-Expressing Breast Cancer |
- Malignant Neoplasm of Breast
|
|
Interventional
|
Phase 1 |
- Daiichi Sankyo Co., Ltd.
- Daiichi Sankyo, Inc.
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Average baseline-adjusted QT interval corrected for heart rate by Fridericia's formula (QTcF )
- Maximum Concentration (Cmax)
- Time to Cmax (Tmax)
- (and 7 more...)
|
50 |
All |
20 Years and older (Adult, Older Adult) |
NCT03366428 |
DS8201-A-J102 |
|
December 26, 2017 |
September 2018 |
April 2019 |
December 8, 2017 |
May 25, 2018 |
|
- Kanagawa Cancer Center
Yokohama, Kanagawa, Japan - National Cancer Center Hospital
Chuo Ku, Tokyo, Japan - The Cancer Institute Hospital of Japanese Foundation For Cancer Research
Koto-Ku, Tokyo, Japan - (and 4 more...)
|
|
| 29 |
NCT03359954 |
Recruiting |
PRECISE: Preoperative Radiotherapy to Elicit Critical Immune Stimulating Effects |
- Malignant Neoplasm of Breast
|
- Radiation: Preoperative Boost (RT)
- Procedure: Breast Surgery
- Radiation: XRT
|
Interventional
|
Phase 2 |
- M.D. Anderson Cancer Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Evaluation of Change in Percent of Tumor-Infiltrating Lymphocytes (TIL)
- Delay Rate of Surgery Following Boost RT
|
20 |
Female |
18 Years and older (Adult, Older Adult) |
NCT03359954 |
2017-0362 |
|
November 16, 2017 |
October 2019 |
October 2020 |
December 2, 2017 |
March 20, 2018 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
|
| 30 |
NCT03289819 |
Not yet recruiting |
Neoadjuvant Pembrolizumab(Pbr)/Nab-Paclitaxel Followed by Pbr/Epirubicin/Cyclophosphamide in TNBC |
- Malignant Neoplasm of Breast
|
- Drug: Pembrolizumab
- Drug: nab-paclitaxel
- Drug: Epirubicin
- Drug: Cyclophosphamide
|
Interventional
|
Phase 2 |
- Institut fuer Frauengesundheit
- Merck Sharp & Dohme Corp.
- Celgene Corporation
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Pathological Complete Response (pCR) rate
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
- Clinical Response
- (and 2 more...)
|
50 |
Female |
18 Years and older (Adult, Older Adult) |
NCT03289819 |
IFG-NIB-01
2016-003102-14
U1111-1188-3915 |
NIB |
October 2017 |
November 2018 |
December 2018 |
September 21, 2017 |
September 21, 2017 |
|
- Department of Gynecology and Obstetrics, Erlangen University Hospital
Erlangen, Bavaria, Germany
|
|
| 31 |
NCT03261323 |
Not yet recruiting |
Breast Reconstruction Following Breast Cancer in Very High Risk Patients |
- Breast Cancer
- Malignant Neoplasm of Breast
|
- Procedure: Immediate Breast Reconstruction
- Procedure: Delayed Breast Reconstruction
- Other: Breast-Q questionnaire
|
Interventional
|
Not Applicable |
- Case Comprehensive Cancer Center
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- optimal timing of reconstruction in patients at a higher risk for developing breast reconstruction surgical complications
- Major complications
- Minor complications
- (and 3 more...)
|
300 |
Female |
19 Years and older (Adult, Older Adult) |
NCT03261323 |
CASE10116 |
|
May 2018 |
July 2022 |
July 2022 |
August 25, 2017 |
February 6, 2018 |
|
- Cleveland Clinic, Case Comprehensive Cancer Center
Cleveland, Ohio, United States
|
|
| 32 |
NCT03207529 |
Not yet recruiting |
Study of BYL719 (Alpelisib) in Combination With Androgen Receptor Inhibitor (Enzalutamide) in Patients With Androgen Receptor (AR)-Positive and PTEN Positive Metastatic Breast Cancer |
- Malignant Neoplasm of Breast
|
- Drug: Alpelisib
- Drug: Enzalutamide
|
Interventional
|
Phase 1 |
- M.D. Anderson Cancer Center
- Novartis
- Astellas Pharma Global Development, Inc.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Tolerated Dose of Alpelisib with Enzalutamide in Patients With Androgen Receptor (AR)-Positive and PTEN Positive Metastatic Breast Cancer
- Profession-Free Survival (PFS) of Alpelisib with Enzalutamide in Patients With Androgen Receptor (AR)-Positive and PTEN Positive Metastatic Breast Cancer
- Clinical Benefit Rate (CBR) of Alpelisib with Enzalutamide in Patients With Androgen Receptor (AR)-Positive and PTEN Positive Metastatic Breast Cancer
|
28 |
All |
18 Years and older (Adult, Older Adult) |
NCT03207529 |
2016-0538 |
|
June 2018 |
June 2020 |
June 2021 |
July 2, 2017 |
May 14, 2018 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
|
| 33 |
NCT03202316 |
Recruiting |
Study of Triple Combination of Atezolizumab + Cobimetinib + Eribulin (ACE) in Patients With Recurrent/Metastatic Inflammatory Breast Cancer |
- Malignant Neoplasm of Breast
|
- Drug: Cobimetinib
- Drug: Atezolizumab
- Drug: Eribulin
|
Interventional
|
Phase 2 |
- M.D. Anderson Cancer Center
- Genentech, Inc.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Tolerated Dose (MTD) of Cobimetinib Plus Atezolizumab and Eribulin (ACE) in Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer
- Overall Response Rate (ORR) of Cobimetinib Plus Atezolizumab and Eribulin (ACE) in Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer
- Clinical Benefit Rate (CBR) of Cobimetinib Plus Atezolizumab and Eribulin (ACE) in Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer
- (and 3 more...)
|
33 |
Female |
18 Years and older (Adult, Older Adult) |
NCT03202316 |
2016-0890
NCI-2017-01601 |
|
August 11, 2017 |
August 2020 |
August 2021 |
June 28, 2017 |
March 21, 2018 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
|
| 34 |
NCT03165487 |
Recruiting |
Comparison of the Breast Tumor Microenvironment |
- Triple Negative Breast Cancer
- Hormone Receptor Positive Malignant Neoplasm of Breast
|
- Other: Breast tissue collection
- Other: Blood sample collection
|
Observational
|
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Number of subjects with significant mean percent change in Tumor Infiltrating Lymphocytes (TILs)
|
30 |
Female |
50 Years and older (Adult, Older Adult) |
NCT03165487 |
AAAO7708 |
|
September 28, 2017 |
March 31, 2019 |
March 31, 2020 |
May 24, 2017 |
January 5, 2018 |
|
- Columbia University Medical Center
New York, New York, United States
|
|
| 35 |
NCT03159195 |
Recruiting |
Ibrance Real World Insights [IRIS] |
- Malignant Neoplasm of Breast
|
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- Progression of patients progression free
|
1 |
Female |
18 Years and older (Adult, Older Adult) |
NCT03159195 |
A5481090 |
IRIS |
June 12, 2017 |
September 30, 2019 |
September 30, 2019 |
May 18, 2017 |
January 31, 2018 |
|
- Pfizer, Inc.
New York, New York, United States
|
|
| 36 |
NCT03109080 |
Recruiting |
Olaparib & Radiation Therapy for Patients Triple Negative Breast Cancer (TNBC) |
- Breast Neoplasms, Triple-Negative
- Breast Neoplasm Malignant Female
- Radiotherapy Side Effect
|
- Drug: Olaparib
- Radiation: Radiation therapy
|
Interventional
|
Phase 1 |
- Institut Curie
- AstraZeneca
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Determination of the Maximal Tolerated Dose of Olaparib administered with concurrent loco regional radiotherapy
- Incidence of Serious Adverse Events (SAEs), graded according to NCI-CTCAE version 4.03 criteria to assess the safety profile of Olaparib administered with concurrent loco-regional radiotherapy.
- Incidence and severity of Adverse Events (AEs), graded according to NCI-CTCAE version 4.03 criteria to assess the safety profile of Olaparib administered with concurrent loco-regional radiotherapy.
- (and 13 more...)
|
24 |
Female |
18 Years and older (Adult, Older Adult) |
NCT03109080 |
IC 2016-01 RadioPARP
2016-001837-28 |
RadioPARP |
July 24, 2017 |
July 2019 |
July 2021 |
April 12, 2017 |
October 10, 2017 |
|
- Institut Curie
Paris, France
|
|
| 37 |
NCT03106077 |
Recruiting |
Mirvetuximab Soravtansine in Localized Triple-Negative Breast Cancer (TNBC) |
- Malignant Neoplasm of Breast
|
- Drug: Mirvetuximab Soravtansine
|
Interventional
|
Phase 2 |
- M.D. Anderson Cancer Center
- National Comprehensive Cancer Network
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response Rate of Mirvetuximab Soravtansine in Participants with Metastatic FRa+ Triple-Negative Breast Cancer (TNBC)
- Pathologic Response of Mirvetuximab Soravtansine in Participants Chemotherapy Insensitive, FRa+ Triple-Negative Breast Cancer (TNBC)
|
57 |
All |
18 Years and older (Adult, Older Adult) |
NCT03106077 |
2016-0683 |
|
June 5, 2017 |
June 2020 |
June 2021 |
April 10, 2017 |
March 6, 2018 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
|
| 38 |
NCT03101748 |
Recruiting |
A Phase 1b Study of Neratinib, Pertuzumab and Trastuzumab With Taxol (3HT) in Primary Metastatic and Locally Advanced Breast Cancer, and Phase II Study of 3HT Followed by AC in HER2 + Primary IBC, and Neratinib With Taxol (NT) Followed by AC in HR+ /HER2- Primary IBC |
- Malignant Neoplasm of Breast
|
- Drug: Neratinib
- Drug: Paclitaxel
- Drug: Pertuzumab
- (and 3 more...)
|
Interventional
|
Phase 1
Phase 2 |
- M.D. Anderson Cancer Center
- Puma Biotechnology, Inc.
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Tolerated Dose (MTD) of Neratinib in Combination with Paclitaxel, Pertuzumab, and Trastuzumab in HER2-positive (HER2+) Primary Metastatic or Locally Advanced Breast Cancer
- Pathologic Complete Response (pCR) Rate of Neratinib in Combination with Paclitaxel, Pertuzumab, and Trastuzumab Followed by Doxorubicin and Cyclophosphamide (AC) in HER2+ Locally Advanced Inflammatory Breast Cancer (IBC) Patients
- Pathologic Complete Response (pCR) Rate of Neratinib in Combination with Paclitaxel Followed by Doxorubicin and Cyclophosphamide in HER2-Negative/ER-Positive (HER2-/ER+) Locally Advanced Inflammatory Breast Cancer (IBC) Patients
- Progression Free Survival (PFS) Rate of HER2+ Primary de novo Metastatic and Locally Advanced Inflammatory Breast Cancer (IBC) Patients, and HER2-/ER+ IBC Patients Treated with Neratinib Plus Anthracycline and Taxane Based Chemotherapy
|
99 |
Female |
18 Years and older (Adult, Older Adult) |
NCT03101748 |
2016-0537
NCI-2017-00813 |
|
January 29, 2018 |
January 2026 |
January 2027 |
April 5, 2017 |
March 21, 2018 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
|
| 39 |
NCT03099174 |
Recruiting |
This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer. |
- Neoplasms
- Breast Neoplasms
|
- Drug: Xentuzumab
- Drug: Abemaciclib
- Drug: Letrozole
- (and 2 more...)
|
Interventional
|
Phase 1 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Cohorts A, B,C & D - Maximum Tolerated Dose (MTD)
- Cohorts A, B,C & D - Number of patients with dose limiting toxicities (DLT) in the Maximum Tolerated Dose (MTD) evaluation period
- Cohorts E & F: objective response (OR), defined as best overall response of complete response (CR) or partial response (PR), where best overall response is determined according to Response Evaluation Criteria In Solid Tumours (RECIST) version 1.1.
- (and 5 more...)
|
88 |
All |
18 Years and older (Adult, Older Adult) |
NCT03099174 |
1280.18
2016-003142-85 |
|
May 4, 2017 |
December 6, 2018 |
July 10, 2020 |
April 4, 2017 |
June 13, 2018 |
|
- Yale University School of Medicine
New Haven, Connecticut, United States - University of Minnesota Masonic Cancer Center
Minneapolis, Minnesota, United States - INS Paoli-Calmettes
Marseille Cedex 9, France - (and 7 more...)
|
|
| 40 |
NCT03088527 |
Recruiting |
A Phase 1, First-in-Human Study of RAD140 in Postmenopausal Women With Hormone Receptor Positive Breast Cancer |
- Hormone Receptor Positive Malignant Neoplasm of Breast
|
|
Interventional
|
Phase 1 |
- Radius Pharmaceuticals, Inc.
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence rate of dose-limiting toxicities (DLTs) RAD140 treatment
- Number of adverse events related to study treatment
- Number participants with dose interruptions and dose adjustments
- (and 4 more...)
|
40 |
Female |
18 Years and older (Adult, Older Adult) |
NCT03088527 |
RAD140-01-001 |
|
October 23, 2017 |
July 2020 |
December 2020 |
March 23, 2017 |
February 14, 2018 |
|
- Yale Cancer Center
New Haven, Connecticut, United States - Cancer Center Protocol Office
Boston, Massachusetts, United States - Barbara Ann Karmanos Cancer Center
Detroit, Michigan, United States - (and 2 more...)
|
|
| 41 |
NCT03077841 |
Recruiting |
Optimizing Preventative Adjuvant Linac-Based Radiation: the OPAL Trial - Study of Hypofractionated Partial Breast Irradiation in Women With Early Stage Breast Cancer |
- Malignant Neoplasm of Breast
- Breast Cancer
|
- Radiation: External Radiation Therapy
- Behavioral: Questionnaires
|
Interventional
|
Phase 2 |
- M.D. Anderson Cancer Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Rate of grade 2 or Higher Treatment Toxicity with Optimizing Preventative Adjuvant Linac-Based Radiation (OPAL) Regimen
- Patient-Reported Cosmetic Outcome with Optimizing Preventative Adjuvant Linac-Based Radiation (OPAL) Regimen
|
150 |
Female |
50 Years and older (Adult, Older Adult) |
NCT03077841 |
2016-1035
NCI-2017-00476 |
|
March 6, 2017 |
March 2020 |
March 2021 |
March 13, 2017 |
May 18, 2018 |
|
- Community Health Network
Indianapolis, Indiana, United States - Cooper University Healthcare
Camden, New Jersey, United States - Ohio Health/Presbyterian MDA Radiation Treatment Center
Columbus, Ohio, United States - (and 7 more...)
|
|
| 42 |
NCT03012399 |
Recruiting |
Biobehavioral Effects of Hypnosis During Breast Cancer Surgery |
- Malignant Neoplasm of Breast
- Breast Cancer
|
- Behavioral: Hypnosedation
- Behavioral: Empathic Conversation
- Behavioral: Questionnaires
|
Interventional
|
Not Applicable |
- M.D. Anderson Cancer Center
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Feasibility of Hypnosedation (HS) During Breast Cancer Surgery
|
50 |
Female |
18 Years and older (Adult, Older Adult) |
NCT03012399 |
2016-0599 |
|
March 7, 2017 |
March 2020 |
March 2021 |
January 6, 2017 |
April 2, 2018 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
|
| 43 |
NCT03007979 |
Recruiting |
Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer |
- Breast Cancer
- Breast Carcinoma
- Cancer of Breast
- Malignant Tumor of Breast
|
- Drug: Palbociclib
- Drug: Letrozole
- Drug: Fulvestrant
- (and 5 more...)
|
Interventional
|
Phase 2 |
- Washington University School of Medicine
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Rate of grade 3 or higher neutropenia
- Rate of palbociclib dose reduction
- Rate of palbociclib dose interruption
- (and 5 more...)
|
47 |
Female |
18 Years and older (Adult, Older Adult) |
NCT03007979 |
201612098 |
|
June 15, 2017 |
July 31, 2019 |
June 30, 2021 |
January 2, 2017 |
May 18, 2018 |
|
- Washington University School of Medicine
Saint Louis, Missouri, United States - University of Nebraska
Lincoln, Nebraska, United States
|
|
| 44 |
NCT02971748 |
Recruiting |
A Study of Anti-PD-1 (Pembrolizumab) + Hormonal Therapy in HR-positive Localized IBC Patients With Non-pCR to Neoadjuvant Chemotherapy |
- Inflammatory Breast Cancer
- Malignant Neoplasm of Breast
|
|
Interventional
|
Phase 2 |
- M.D. Anderson Cancer Center
- Merck Sharp & Dohme Corp.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Disease-free survival (DFS)
|
37 |
All |
18 Years and older (Adult, Older Adult) |
NCT02971748 |
2016-0096 |
|
January 26, 2017 |
January 2020 |
January 2021 |
November 23, 2016 |
February 28, 2018 |
|
- The University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
|
| 45 |
NCT02949310 |
Recruiting |
Effectiveness of Nefopam in Breast Cancer Surgery |
- Breast Neoplasm Malignant Primary
|
- Drug: Nefopam
- Drug: Normal Saline
|
Interventional
|
Not Applicable |
- Seoul National University Bundang Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Supportive Care
|
- Change of cumulative analgesia volume infused via intravenous patient-controlled analgesia device
- Change of numerical rating scale for postoperative pain
|
88 |
Female |
20 Years and older (Adult, Older Adult) |
NCT02949310 |
Nefo-TM & MRM |
|
October 2016 |
December 2018 |
December 2018 |
October 31, 2016 |
January 11, 2018 |
|
- Seoul National University Bundang Hospital
Seongnam, Gyeonggi, Korea, Republic of
|
|
| 46 |
NCT02912312 |
Recruiting |
Shortening Adjuvant Photon Irradiation to Reduce Edema (SAPHIRE): Hypofractionated Versus Conventionally Fractionated Regional Nodal Irradiation for Invasive Breast Cancer |
- Malignant Neoplasm of Breast
|
- Radiation: Radiation Therapy
- Behavioral: Questionnaires
|
Interventional
|
Phase 2 |
- M.D. Anderson Cancer Center
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Comparison of Lymphedema Rate During and After Completion of RNI Between Participants Randomized to Short Versus Standard RNI
|
290 |
Female |
18 Years and older (Adult, Older Adult) |
NCT02912312 |
2016-0142
NCI-2016-01941 |
|
February 23, 2017 |
February 2030 |
February 2031 |
September 23, 2016 |
March 15, 2018 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
|
| 47 |
NCT02891681 |
Recruiting |
Ultrasound and Near Infrared Imaging for Predicting and Monitoring Neoadjuvant Treatment |
- Breast Cancer
- Breast Tumors
- Cancer of Breast
- (and 2 more...)
|
- Device: Optical Tomography Using Near Infrared Diffused Light Assisted with Ultrasound
|
Interventional
|
Phase 1 |
- Washington University School of Medicine
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Pathologic response based on Miller-Payne grading system
|
50 |
Female |
18 Years and older (Adult, Older Adult) |
NCT02891681 |
201608101 |
|
November 29, 2016 |
May 31, 2019 |
May 31, 2019 |
September 7, 2016 |
September 15, 2017 |
|
- Washington University School of Medicine
Saint Louis, Missouri, United States
|
|
| 48 |
NCT02876107 |
Recruiting |
A Phase II Study of Using Panitumumab/Carboplatin/Paclitaxel (PaCT) Followed by Anthracycline-Containing Regimen (AC) for New Triple-Negative Inflammatory Breast Cancer (TN-IBC) |
- Malignant Neoplasm of Breast
|
- Procedure: Breast Core Biopsy
- Drug: Paclitaxel
- Drug: Carboplatin
- (and 6 more...)
|
Interventional
|
Phase 2 |
- M.D. Anderson Cancer Center
- Amgen
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Complete Pathologic Response (pCR) Rate
- Disease-Free Survival (DFS) Rate
|
72 |
Female |
18 Years and older (Adult, Older Adult) |
NCT02876107 |
2016-0177
NCI-2017-00619 |
|
October 2016 |
October 2023 |
October 2024 |
August 23, 2016 |
February 19, 2018 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
|
| 49 |
NCT02789332 |
Recruiting |
Assessing the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination Deficiency |
- Breast Cancer
- Triple Negative Breast Neoplasms
- HRpos Breast Neoplasms
- BRCA 1 /2 and / or HRD
|
- Drug: PwO
- Drug: PwCb
- Drug: EC
- (and 2 more...)
|
Interventional
|
Phase 2 |
- German Breast Group
- AstraZeneca
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- response by pCR =ypT0/is ypN0
- response by pCR =ypT0/is ypN0 in stratified subgroups
- response by pCR according to other definitions
- (and 4 more...)
|
102 |
All |
18 Years and older (Adult, Older Adult) |
NCT02789332 |
GBG90 |
GeparOla |
September 2016 |
November 2018 |
November 2018 |
June 3, 2016 |
June 27, 2017 |
|
- Kliniken Esslingen, Gynäkologie Onkologie
Esslingen am Neckar, Baden-Württemberg, Germany - Universitätsklinikum Erlangen
Erlangen, Bayern, Germany - Onkologisches Zentrum am Rotkreuzklinikum München
München, Bayern, Germany - (and 9 more...)
|
|
| 50 |
NCT02744053 |
Recruiting |
Multimodality Breast Imaging for the Assessment of Tumor Response to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer Patients |
- Breast Cancer
- Malignant Neoplasm of Breast
|
- Procedure: Dynamic Contrast Enhanced Molecular Resonance Imaging (DCE-MRI)
- Procedure: Tc99m Sestamibi Molecular Breast Imaging (MBI)
- Drug: 99mTc Sestamibi
|
Interventional
|
Early Phase 1 |
- M.D. Anderson Cancer Center
- GE Healthcare
- Mayo Clinic
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Assessment of Response to Neoadjuvant Chemotherapy (NAC) Using Tc99m Sestamibi Molecular Breast Imaging (MBI) and Dynamic Contrast Enhanced Molecular Resonance Imaging (DCE-MRI)
|
100 |
All |
18 Years and older (Adult, Older Adult) |
NCT02744053 |
2015-0816
NCI-2016-00715 |
|
November 2016 |
November 2020 |
November 2020 |
April 20, 2016 |
November 7, 2017 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
|
Create an RSS feed from your search for:
Download the search results for: